TP53 and thyroid gland carcinoma: P53 mutation is a marker of aggressive thyroid cancers [1, 3] and effects of siRNA-mediated kinase knock-down were not dependent on functional P53 because some of the used cell lines were P53-mutated (Supplemental Information, Table S4).